

University of Groningen

Pelvic Organ Prolapse

Panman, Chantal; Wiegersma, Marian

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2017

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Panman, C., & Wiegersma, M. (2017). *Pelvic Organ Prolapse: Conservative treatments in primary care*. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

CHAPTER 3

EFFECT OF PELVIC FLOOR MUSCLE TRAINING
COMPARED WITH WATCHFUL WAITING IN
OLDER WOMEN WITH SYMPTOMATIC MILD
PELVIC ORGAN PROLAPSE: RANDOMISED
CONTROLLED TRIAL IN PRIMARY CARE

Marian Wiegersma, Chantal M.C.R. Panman, Boudewijn J. Kollen,
Marjolein Y. Berger, Yvonne Lisman-Van Leeuwen, Janny H. Dekker

ABSTRACT

Objective

To compare the effects of PFMT and watchful waiting on pelvic floor symptoms in a primary care population of women aged 55 years and over with symptomatic mild prolapse.

Design, setting and participants

Randomised controlled trial in Dutch primary care. Women aged 55 years or over with symptomatic mild prolapse (leading edge above the hymen) were identified by screening.

Interventions

PFMT versus watchful waiting.

Main outcome measures

The primary outcome was change in bladder, bowel, and pelvic floor symptoms measured with the PFDI-20, three months after the start of treatment. Secondary outcomes were changes in condition specific and general quality of life, sexual function, degree of prolapse, pelvic floor muscle function, and patients' perceived change in symptoms.

Results

Of the 287 women who were randomised to PFMT ($n = 145$) or watchful waiting ($n = 142$), 250 (87%) completed follow-up. Participants in the intervention group improved by (on average) 9.1 (95% CI 2.8 to 15.4) points more on the PFDI-20 than did participants in the watchful waiting group ($p = 0.005$). Of women in the pelvic floor muscle training group, 57% (82/145) reported an improvement in overall symptoms from the start of the study compared with 13% (18/142) in the watchful waiting group ($p < 0.001$). Other secondary outcomes showed no significant difference between the groups.

Conclusions

Although PFMT led to a significantly greater improvement in PFDI-20 score, the difference between the groups was below the presumed level of clinical relevance (15 points). Nevertheless, 57% of the participants in the intervention group reported an improvement of overall symptoms. More studies are needed to identify factors related to success of PFMT and to investigate long term effects.

INTRODUCTION

Prolapse is a common condition characterised by descent of the anterior or posterior vaginal wall, the uterus, or the vaginal vault (after hysterectomy).¹ In a Dutch community survey, 75% of women aged 45-85 years had some degree of prolapse.² The prevalence of typical symptoms of prolapse (seeing or feeling a vaginal bulge) is reported to be about 3-12%.^{2,3} Typical prolapse symptoms are thought to emerge when the leading edge of the prolapse is at or below the hymen.^{4,5} Women with milder forms of prolapse more often experience other common prolapse related symptoms such as pelvic pressure/heaviness or pelvic pain and urinary or bowel symptoms. Treatment options include conservative management (PFMT or pessary treatment) and surgical correction. However, surgery is associated with several problems. Comorbidity and frailty can make surgery undesirable, and risks of complications and recurrence are considerable. Finally, costs for prolapse related surgery are high and are expected to substantially increase owing to the ageing population and the higher prevalence of prolapse in older women.⁶ As women with mild prolapse often experience mild symptoms, surgery is generally not an option. However, evidence suggests that women with symptomatic mild prolapse might benefit from PFMT.^{7,8} There are two main hypotheses on how PFMT may be effective in the treatment of prolapse: descent of the pelvic floor is prevented by teaching women to consciously contract their pelvic floor muscles before and during any increase in abdominal pressure; and structural support of the pelvic floor is improved by the performance of pelvic floor muscle exercises, and, as a result, the pelvic organs are held in place better.⁹ Beneficial effects of PFMT in symptomatic stage 1 and/or 2 prolapse were shown in three small studies, of which two were pilot studies^{7,8} and the other was of moderate methodological quality.¹⁰ Other studies investigating the effect of PFMT on prolapse also included women without symptoms, women with more severe stage prolapse (at or below the hymen), or both.¹¹⁻¹⁴

PFMT could typically be applied in primary care. However, high quality studies on the effectiveness of PFMT in women with symptomatic (mild) prolapse in this setting are lacking. The aim of this study was to compare the effects of PFMT and watchful waiting on pelvic floor symptoms in a primary care population of women aged 55 years or over with symptomatic mild prolapse.

METHODS

This was a randomised controlled trial comparing PFMT and watchful waiting in women aged 55 years or over with symptomatic mild prolapse. All participants gave written informed consent. The study design has been published in detail elsewhere.¹⁵

Participants

Participants were recruited from 15 Dutch general practices between 14 October 2009 and 19 October 2012. Participating general practitioners selected all women aged at least 55 years who did not meet the study's exclusion criteria. These included current prolapse treatment or treatment in the previous year, pelvic organ malignancy, current treatment for another gynaecological disorder, severe/terminal illness, impaired mobility, cognitive impairment, and insufficient command of the Dutch language. The remaining women received a postal five item screening questionnaire (Appendix I) asking about vaginal bulging, pelvic heaviness, urinary incontinence, and vaginal splinting to assist micturition or defecation. Women who responded positively to one or more screening questions were invited to fill in another questionnaire and visit for a baseline assessment.

A standardised interview about demographics and medical and obstetric history was performed. Additionally, all women underwent a physical examination and urinalysis for urinary tract infection. When urinalysis showed a urinary tract infection, participants were treated with antibiotics and afterwards filled in a new questionnaire (which replaced the original baseline questionnaire). The baseline physical examination comprised measurement of post-void residual volume with an abdominal ultrasound (BladderScan), evaluation of pelvic floor muscle function,¹⁶ and POP-Q measurement.¹⁷ Physical examinations were performed by research physicians who were trained in POP-Q measurement and pelvic floor muscle function assessment by an experienced urogynaecologist. Women with mild prolapse, defined as the leading edge of the prolapse staying above the hymen (POP-Q stage 1 and mild stage 2), were eligible for randomisation.

Interventions

Pelvic floor muscle training

Pelvic physiotherapists registered with the Dutch Pelvic Physiotherapists' Organisation treated all participants randomised to PFMT. These physiotherapists complete a three year specialisation course in the diagnosis and treatment of pelvic floor disorders. PFMT was provided individually in face-to-face contacts combined with home exercises. The pelvic physiotherapists recorded the treatment modalities and the number of treatment sessions for each participant. For all participants, the intervention started with an explanation of the function of the pelvis and the pelvic floor and about pelvic floor dysfunctions; illustrations and three dimensional models of the pelvis were used. Pelvic floor muscle function was assessed by digital palpation. During this examination, the physiotherapists also checked whether participants were able to correctly contract ("squeeze and lift") and relax their pelvic floor muscles.

If necessary, they used breathing exercises to increase awareness of the pelvic floor. Participants who were not able to contract or relax their pelvic floor muscles were first instructed how to do this by being given feedback during digital palpation or, if necessary, by application of myofeedback or electrical stimulation. Participants who were able to control their pelvic floor consciously but whose pelvic floor muscles were too weak started training their pelvic floor by doing exercises. All participants started with the same basic exercise scheme, to which specific exercises could be added (Appendix II). The exercise programme was individualised and was modified at each appointment on the basis of examination findings. In cases of an overactive pelvic floor, the focus of the exercises was on relaxation rather than on contraction and, if necessary, general relaxation exercises were used. All participants were taught to contract their pelvic floor muscles before and during any increases in abdominal pressure ("the knock"), and attention was paid to lifestyle (diet, body weight) and toilet habits (Appendix II). Initially, participants visited the pelvic physiotherapist on a weekly basis, but when they were able to correctly contract and relax their pelvic floor muscles the intervals between appointments were extended (two to three weeks). Participants were encouraged to continue practising at home three to five times a week, twice or three times each day.

Watchful waiting

Participants randomised to watchful waiting received no treatment and no recommendations.

Follow-up

Participants were scheduled for a follow-up appointment with the research physician three months after the start of treatment (or, in case of watchful waiting, three months after randomisation). During the study period, participants were allowed to visit their general practitioner or other caregiver for any symptoms of prolapse; such visits were recorded at follow-up.

Outcomes

The primary outcome of this trial was change in bladder, bowel, and pelvic floor symptoms three months after the start of treatment. Secondary outcomes were changes in condition specific and general quality of life, sexual functioning, degree of prolapse, pelvic floor muscle function, and patients' perceived change in symptoms from the start of the study.

Measurements

We measured change in bladder, bowel, and pelvic floor symptoms with the PFDI-20.

This patient completed questionnaire comprises three subscales with scores ranging from 0 to 100: the POPDI-6 assessing prolapse symptoms, the CRADI-8 assessing colorectal/anal symptoms, and the UDI-6 assessing urinary symptoms. A higher PFDI-20 score (sum of three subscale scores, range 0-300) indicates a higher symptom burden.¹⁸ We measured the effect of bladder, bowel, and pelvic floor symptoms on daily life with the PFIQ-7 (range 0-300, with higher scores indicating greater effect).¹⁸ We used the MOS-SF-12 version 1 to measure general quality of life.^{19,20} We measured sexual functioning with the PISQ-12 (range 0-48, with higher scores indicating better sexual functioning).²¹ We assessed patients' perceived change in symptoms from the start of the study by using three questions (are symptoms the same/better/worse?) with visual analogue scale scores for improvement/deterioration (on a scale from 0-10). We used the POP-Q system to assess the degree of prolapse at baseline and follow-up. In the POP-Q system, the degree of prolapse of the anterior vaginal wall, the posterior vaginal wall, and the uterus or vaginal vault (when there is a history of hysterectomy) is measured in centimetres, using the hymenal remnants as a reference point. Additionally, the genital hiatus, the perineal body, and the total vaginal length (with the prolapse reduced) are measured. On the basis of these findings, a POP-Q stage (0-4) is calculated for each compartment. The overall POP-Q stage is equal to the POP-Q stage of the most severely prolapsed compartment.¹⁷ Pelvic floor muscle function was examined by vaginal palpation of the pelvic floor muscles in the lithotomy position. We defined pelvic floor muscle function as normal (voluntary contraction normal/strong, voluntary relaxation complete, involuntary contraction and involuntary relaxation present), underactive (voluntary contraction absent/weak, voluntary relaxation complete, involuntary contraction absent/present, and involuntary relaxation present), overactive (voluntary contraction absent/weak/normal/strong, voluntary relaxation absent/partially present, involuntary contraction and involuntary relaxation absent/present), or inactive (voluntary contraction absent, voluntary relaxation complete, involuntary contraction and involuntary relaxation absent).¹⁶

Sample size

To detect a difference of 15 points (25% reduction in the PFDI-20 score assuming a PFDI-20 baseline score of 60 points and no change in the watchful waiting group¹⁵) with a standard deviation of 36 points,²² a power of 80%, and a two sided α of 0.05, we needed 92 women in each treatment arm. Allowing for a dropout rate of 15%, we needed a total of 216 women for this trial.

Randomisation

We used blocked randomisation with variable block sizes to randomise participants

to one of the treatment arms in a one to one ratio. An independent statistician who was not involved in the enrolment of participants generated an allocation sequence. The research physician used an external computer system with an interactive voice response system (accessible by telephone) to enrol participants in the study. This research physician was blinded to allocation sequence and to both the ordering of the blocks and their sizes.

Blinding

Participants, pelvic physiotherapists, and research physicians were not blinded to group allocation. Research physicians and pelvic physiotherapists were blinded to all answers on the participant completed questionnaires, and research physicians were blinded to the outcomes of the previous POP-Q measurements and previous evaluations of pelvic floor muscle function.

Statistical methods

We compared the difference in the change of questionnaire scores (PFDI-20, PFIQ-7, PISQ-12, physical and mental component summary scores of general quality of life) from baseline to follow-up between groups by analysis of covariance using the follow-up score as the dependent variable and baseline score, baseline POP-Q stage (1 or 2), and previous prolapse treatment (more than one year previously) (yes/no) as covariates.²³ For the PFIQ-7 scores, we used a square root transformation to obtain a normal distribution of the residuals. We used logistic regression analysis to assess whether patient perceived improvement or worsening of symptoms, improvement or worsening of POP-Q stage, and improvement or worsening of pelvic floor muscle function (dependent variables) were predicted by randomisation group (independent variable). We applied a Bonferroni correction to correct the reported *p*-values for multiple testing.

We defined improvement/worsening of the POP-Q stage as improvement or worsening of one or more POP-Q stages (calculated for each compartment). We defined improvement of pelvic floor muscle function as a change from abnormal (underactive/overactive/inactive) at baseline to normal at follow-up and worsening of pelvic floor muscle function as a change from normal at baseline to abnormal at follow-up. We imputed missing values in primary and secondary outcomes by multiple imputation. The imputation model was based on a missing value analysis and included the primary and secondary outcomes of the study and the following variables: treatment group, age, BMI, parity, and previous prolapse treatment. We compared results of the analyses on the non-imputed dataset and analyses after multiple imputation to assess the effect of multiple imputation on the outcomes.

We did all analyses according to the intention to treat principle. We used a $p < 0.05$ significance level for all statistical tests. We used SPSS Statistics for Windows, version 20.0, for the analyses.

RESULTS

In total, 145 women were allocated to PFMT and 142 women to watchful waiting (Figure 1). Table 1 shows the baseline characteristics of the study population. Follow-up questionnaires were completed by 250 (87%) participants, and the follow-up appointment was attended by 237 (83%). Median time from the start of treatment to completing the questionnaires was 3.6 (IQR 3.0-4.3) months for women in the PFMT group and 3.2 (IQR 3.2-3.6) months in the watchful waiting group. In total, 11 (8%) participants did not receive PFMT and 19 (13%) discontinued the intervention prematurely (Figure 2). For participants who completed the PFMT intervention, the median number of treatments was 7 (IQR 5-9). Myofeedback was used in 23 (16%) participants, and electric stimulation was used in 11 (8%). At follow-up, 59 (41%) participants had not yet finished PFMT.

In the intention to treat analysis, participants in the PFMT group showed (on average) a 9.1 point greater improvement on the PFDI-20 scale than participants in the watchful waiting group ($p < 0.005$). For the subscales, the difference between PFMT and watchful waiting was significant on the UDI-6 but not on the POPDI-6 or CRADI-8. Sexual functioning (PISQ-12) and the physical and mental component summary scores of general quality of life did not change over time. Condition specific quality of life (PFIQ-7) improved in both groups (difference not significant) (Table 2). Of the participants in the PFMT group, 57% reported an improvement in symptoms from the start of the study. In the watchful waiting group, improvement was reported by only 13%, and 81% of the participants reported that their symptoms remained the same (Table 3). The visual analogue scale scores of improvement/deterioration showed no significant difference between the groups (data not shown).

At follow-up, the proportion of participants with an improvement of one or more POP-Q stages showed no difference between the groups for any of the compartments (Table 4). The proportion of women with deterioration of one or more POP-Q stages was also the same in both groups for all compartments. The proportion of women in whom pelvic floor muscle function improved from baseline to follow-up was the same in both groups in both the non-imputed and imputed datasets (non-imputed: PFMT 27/106 (25%) versus watchful waiting 18/124 (15%) (corrected $p = 0.117$); imputed: PFMT 35/145 (24%) versus watchful waiting 21/142 (15%) (corrected $p = 0.213$)). The proportion of women in whom pelvic floor muscle function deteriorated between




FIGURE 1 FLOW OF PARTICIPANTS THROUGH STUDY

*No follow-up questionnaire available

TABLE 1 BASELINE CHARACTERISTICS OF ALL PARTICIPANTS.

	PFMT n = 145	Watchful waiting n = 142
Age (years), mean \pm SD	64.5 \pm 6.8	64.0 \pm 6.5
BMI (kg/m ²), mean \pm SD	27.0 \pm 4.7	26.6 \pm 4.8
Parity, mean \pm SD	2.4 \pm 1.2	2.4 \pm 1.1
Postmenopausal, n (%)	142 (98)	140 (99)
Educational level, n (%)		
Primary only	13 (9)	8 (6)
Lower	51 (35)	51 (36)
Intermediate	38 (26)	37 (26)
Higher	43 (30)	46 (32)
Surgical history, n (%)		
Hysterectomy	30 (21)	24 (17)
Pelvic floor surgery	13 (9)	6 (4)
Prior prolapse treatment, n (%)	25 (17)	18 (13)
Stage of prolapse, n (%) [*]		
Stage 1	70 (48)	85 (60)
Stage 2	75 (52)	57 (40)
Type of prolapse, n (%)		
Anterior	77 (53)	75 (53)
Posterior	6 (4)	6 (4)
Apical	1 (1)	1 (1)
Anterior and posterior	30 (21)	31 (22)
Anterior and apical	22 (15)	19 (13)
Posterior and apical	2 (1)	4 (3)
Anterior and posterior and apical	6 (4)	6 (4)
PFDI-20 score, mean \pm SD	65.2 \pm 39.9	59.0 \pm 32.2
POPDI-6 score, mean \pm SD	15.5 \pm 13.4	13.6 \pm 12.4
CRADI-8 score, mean \pm SD	17.2 \pm 15.3	16.2 \pm 14.4
UDI-6 score, mean \pm SD	32.4 \pm 19.7	29.4 \pm 15.8

^{*}Surgical or conservative prolapse treatment > 1 year ago; [†]POP-Q stage of most prolapsed compartment

TABLE 2 CHANGE IN QUESTIONNAIRE SCORES FROM BASELINE TO FOLLOW-UP

	PFMT						Watchful waiting				Difference in mean change from baseline*			
	Baseline			Follow-up			Baseline		Follow-up		Unimputed data		Imputed data	
	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD	Mean (95% CI)	p-value	Mean (95% CI)	p-value
PFDI-20	140	65.2 ± 39.9	117	46.9 ± 37.4	138	59.0 ± 32.2	127	51.3 ± 29.7			-11.0 (-16.6 to -5.4)	<0.001	-9.1 (-15.4 to -2.8)	0.005
POPDI-6	145	15.5 ± 13.4	118	10.5 ± 12.3	141	13.6 ± 12.4	129	11.4 ± 11.3			-2.6 (-4.9 to -0.4)	0.024	-2.0 (-4.5 to 0.5)	0.110
CRADI-8	144	17.2 ± 15.3	118	13.7 ± 15.3	140	16.2 ± 14.4	128	13.6 ± 12.7			-1.4 (-3.7 to 0.8)	0.209	-1.8 (-4.3 to 0.7)	0.165
UDI-6	141	32.4 ± 19.7	118	22.8 ± 17.2	140	29.4 ± 15.8	129	26.3 ± 15.5			-6.0 (-9.1 to -2.9)	<0.001	-5.0 (-8.6 to -1.4)	0.007
PFIQ-7	139	22.1 ± 39.9	110	18.0 ± 36.1	131	12.1 ± 17.9	120	11.7 ± 23.7			0.04 (-0.1 to 0.5)	0.441	0.03 (-0.5 to 1.1)	0.478
PISQ-12†	64	35.5 ± 5.3	43	35.5 ± 6.4	70	36.4 ± 5.4	58	37.1 ± 4.6			0.2 (-1.1 to 1.5)	0.715	-0.1 (-2.3 to 2.1)	0.925
PCS-12	122	45.1 ± 10.5	111	46.5 ± 10.3	130	46.8 ± 9.7	121	46.6 ± 10.4			1.5 (-0.4 to 3.5)	0.125	0.6 (-1.8 to 3.0)	0.606
MCS-12	122	52.7 ± 8.5	111	53.4 ± 7.1	130	52.8 ± 8.5	121	53.7 ± 8.3			-0.6 (-2.3 to 1.0)	0.446	-0.9 (-2.7 to 0.8)	0.307

* Adjusted for baseline score, baseline POP-Q stage, and previous prolapse treatment (> 1 year ago); †PISQ-12 score only available for women who were sexually active, missing scores were only imputed for women who were sexually active at baseline

baseline and follow-up was the same in both groups (data not shown).

No participants reported any adverse effects of PFMT.

DISCUSSION

Women with mild prolapse who received PFMT showed greater improvement in symptoms than did women randomised to a watchful waiting strategy. Although the difference between the groups (9.1 points) was significant, it was below the presumed level of clinical relevance (15 points). Nevertheless, 57% of women in the PFMT group reported symptomatic improvement compared with only 13% in the watchful waiting group. However, because this patient reported outcome may be susceptible to recall bias and social desirability bias, these results need to be interpreted with caution. Nevertheless, women receiving PFMT seemed to gain more insight into their symptoms and underlying condition, leading to a higher subjective appreciation of improvement than was reflected in the change in PFDI-20 scores. Another possibility is that a subgroup of women benefit from PFMT, whereas others do not experience any improvement. Further research might identify factors related to the success of PFMT.

Typical symptoms of prolapse (such as seeing or feeling a vaginal bulge) are thought to emerge when the leading edge of the prolapse is at or below the hymen.^{4,5} Therefore, in women with mild prolapse, other common prolapse related symptoms, such as urinary and bowel symptoms, should be assessed. In this study, in women with mild prolapse, PFMT mainly affected the urinary symptoms. The largest difference in mean change from baseline was achieved in the PFDI-20 subscale measuring urinary

TABLE 3 SELF-REPORTED CHANGE IN SYMPTOMS SINCE THE START OF THE STUDY

	Unimputed data			Imputed data		
	PFMT n/N (%)	Watchful waiting n/N (%)	p-value*	PFMT† n/N (%)	Watchful waiting† n/N (%)	p-value*
Better	70/115 (61)	10/124 (8)	<0.001	82/145 (57)	18/142 (13)	<0.001
The same	43/115 (37)	106/124 (85)	<0.001	58/145 (40)	115/142 (81)	<0.001
Worse	2/115 (2)	8/124 (6)	0.270	16/145 (11)	17/142 (12)	1.000

*Logistic regression analysis, corrected p-value (Bonferroni); †Owing to multiple imputation, the percentages do not add up to 100%

TABLE 4 NUMBER OF PARTICIPANTS WITH IMPROVEMENT OF 1 OR MORE POP-Q STAGES

Compartment		PFMT n/N (%)	Watchful waiting n/N (%)	p-value*
Anterior	Unimputed data	29/107 (27)	20/128 (16)	0.099
	Imputed data	39/145 (27)	24/142 (17)	0.222
Posterior	Unimputed data	10/106 (9)	14/128 (11)	1.000
	Imputed data	13/145 (9)	14/142 (10)	1.000
Apical	Unimputed data	15/107 (14)	20/127 (16)	1.000
	Imputed data	23/145 (16)	22/142 (15)	1.000

*Logistic regression analysis, corrected p-value (Bonferroni)

symptoms (UDI-6). The other PFDI-20 subscales (measuring prolapse and bowel symptoms) showed no significant differences in change between the groups. The relation between prolapse and urinary symptoms is not yet completely understood. Although stress urinary incontinence and prolapse are thought to be two coexisting problems that share causative factors rather than having a cause and effect relation,²⁴ prolapse might cause bladder outlet obstruction, leading to irritable bladder symptoms (urgency, urge incontinence, frequency, nocturia).²⁵ Stress urinary incontinence is more common in women with mild prolapse,^{26, 27} whereas irritable bladder symptoms are thought to be more common in women with advanced prolapse.²⁵

Strengths and limitations of study

The main strengths of this study are its sample size, its pragmatic design with patient oriented outcome measures, and the fact that it is the first study to compare PFMT and watchful waiting in a primary care population of women with a symptomatic mild prolapse. The study also has some limitations. Because many women with prolapse symptoms do not consult a physician,²⁸ we chose to screen women for symptoms possibly related to prolapse. Consequently, because some women in our study population experienced only mild symptoms at baseline, the mean PFDI-20 baseline score was lower than those reported in similar studies. This might have led to an underestimation of the effect of PFMT because little room for improvement exists when symptoms are mild at baseline.

Another limitation is that we did not use a standard PFMT protocol. Instead, we chose a pragmatic approach in which the participating pelvic physiotherapists tailored the treatment to the needs of each participant. To minimise the effect of any possible differences between pelvic physiotherapists as regards their experience or skills, the pelvic physiotherapists had to be registered with the Dutch Pelvic Physiotherapists'

Organisation. As a consequence, all participants were trained according to the same basic exercise scheme. However, because we did not register the amount of home exercises performed by the participants, we do not know how strictly the participants adhered to their home exercise programme.

Women in the control group received no active treatment or recommendations. This choice was also pragmatic; because women with mild prolapse often do not qualify for pessary treatment or surgical correction, watchful waiting would be usual practice for many women with symptomatic mild prolapse. We do not know to what extent women in the watchful waiting group were influenced by the information they received about prolapse at baseline; better understanding of their condition (for example, knowing that they had a mild prolapse and what this means) and its treatment options might have led to an improvement in symptom burden. They may also have started doing pelvic floor home exercises by themselves; however, as this would also be the case in usual practice it is probably not a great disadvantage.

Finally, the effect of PFMT compared with watchful waiting was assessed after three months of treatment. However, as not all participants had finished PFMT at the moment of follow-up, the difference between the groups might increase as the maximal effect of PFMT had not yet been achieved. Also, rather than relieving symptoms, PFMT might prevent symptoms from getting worse. This implies that symptoms in the PFMT group would remain stable whereas those in the watchful waiting group would get worse over time; this might also apply to the degree of prolapse. However, the period of follow-up in this study was too short to establish such a difference between the groups. We found no difference in the change in pelvic floor muscle function between the groups; this might also be related to the duration of follow-up. Another possible explanation is that the method we used for measuring pelvic floor muscle function may not be sufficiently sensitive to small changes in pelvic floor muscle function. However, as the clinical relevance of these small changes is questionable, we think the method we used was appropriate.

Comparison with other studies

To date, only three small studies have evaluated the effect of PFMT on mild prolapse. Hagen et al. reported a pilot study in which 47 women with a symptomatic stage 1-2 prolapse were randomised to PFMT ($n = 23$) or to a postal lifestyle advice sheet ($n = 24$).⁷ Stüpp et al. reported a pilot study in which 37 women with a stage 2 prolapse were randomised to PFMT ($n = 21$) or control ($n = 16$); women in the control group did not consult a physiotherapist but received instructions on how to perform pelvic floor muscle contractions and a lifestyle advice leaflet.⁸ Ghroubi et al. reported a trial in which 47 women with stage 1-2 prolapse of the anterior vaginal wall were randomised

to PFMT (n = 27) or no treatment (n = 20).¹⁰ All three studies showed beneficial effects of PFMT on symptoms; however, as two of them were small pilot studies and the other was of moderate methodological quality, these results need to be confirmed in larger samples. Furthermore, as all these studies were conducted in a hospital setting, their conclusions might not be generalisable to the primary care population.

More studies have investigated the effect of PFMT on more severe stages of prolapse. The most rigorous trial so far was by Hagen et al.,¹⁴ who randomised 447 women with symptomatic stage 1-3 prolapse to PFMT or a lifestyle leaflet. Follow-up was at six and 12 months, and participants could be referred for further treatment at six months. PFMT led to a significantly greater reduction in prolapse symptoms, with a difference in mean change from baseline of 1.52 points on the Pelvic Organ Prolapse Symptom Score between the groups (minimal clinically important difference = 1.5²⁹). No difference was seen in improvement of bladder and bowel symptoms at 12 months. The results of this trial are probably not generalisable to the primary care population of women with mild prolapse (above the hymen), as participants were recruited in a hospital setting and 70% of them had an advanced prolapse (at or below the hymen). Two other trials compared PFMT with a control intervention. Braekken et al. enrolled 109 women with stage 1-3 prolapse who attended a gynaecologist with prolapse symptoms or for a routine check-up and also women who were just interested to know if they had a prolapse. Women in the control group were advised to avoid straining and were taught how to contract their pelvic floor muscles before and during increases in abdominal pressure (the knock).¹¹ Kashyap et al. randomised 140 women with stage 1-3 prolapse who attended a gynaecology outpatient department with prolapse symptoms. Women in the control group received a self instruction manual with a home exercise programme but no sessions with a pelvic physiotherapist.¹² In both studies, PFMT resulted in a greater improvement in symptoms than did the control intervention. However, because both studies included both asymptomatic women and women with more severe stages of prolapse, these results are probably also not generalisable to the primary care population of women with only mild prolapse. Finally, Piya-Anant et al. randomised 320 women with mild or advanced prolapse to PFMT and 324 to control.¹³ Despite the sample size, this study had considerable methodological shortcomings, and, as it did not consider the effects of PFMT on symptoms, the results cannot be compared with those of our study.

Clinical interpretation of results

Although we found a significant difference between the groups, this difference is probably not clinically relevant. Very limited literature is available on the minimal clinically important difference for the PFDI-20 questionnaire in women with mild

prolapse. In the design phase of this trial, we assumed a difference of 15 points between groups to be clinically relevant. The between treatment minimal clinically important difference can be defined as the difference between the mean change in PFDI-20 score in participants who report that their symptoms are “the same” and those who report that symptoms are “a little better” at follow-up compared with baseline. Gelhorn et al. studied the psychometric properties of the PFDI-20 in two different populations of women undergoing prolapse surgery, with baseline scores of 114.8 and 97.1, and found between treatment minimal clinically important differences of 7.5 points and 17.3 points, respectively.³⁰ Utomo et al. studied the PFDI-20 in women with one or more pelvic floor symptoms who were recruited in a tertiary urology and gynaecology clinic. They found a between treatment minimal clinically important difference of 19 points in a subgroup of patients undergoing (conservative or surgical) treatment (baseline score 94.1 points: personal communication E Utomo, 5 June 2014).³¹ However, as the minimal clinically important difference may vary by population and by context,³² these numbers might not be generalisable to our primary care study population in which PFDI-20 baseline scores were considerably lower. We used a three point scale to assess patients' perceived change of symptoms from the start of the study (the same/better/worse). The difference in the change in PFDI-20 score between women who reported that symptoms were “the same” and those who reported that they were “better” was 15.2 points. On the basis of these findings, the difference between PFMT and watchful waiting found in our study does not seem to be clinically relevant. However, as the category “a little better” was not available in our questionnaire, the actual between treatment minimal clinically important difference of the PFDI-20 questionnaire in a primary care population might be lower. Therefore, we do not know for sure whether the detected difference of 9.1 points is clinically relevant in this population.

Conclusions and policy implications

This is the first study to investigate the effects of PFMT in a primary care population of women with symptomatic mild prolapse, who were identified by screening. We found a significant but presumably not clinically relevant difference in the change in symptoms (PFDI-20) between the groups. Nevertheless, as 57% of the participants in the PFMT group reported that their symptoms had improved, PFMT might be considered for the treatment of women with bothersome symptomatic mild prolapse who do not qualify for pessary treatment or surgical correction. Further research might identify factors related to the success of PFMT. Additionally, more research on long term follow-up is needed to investigate whether the effects of PFMT are sustained on the long term and to establish whether PFMT can prevent symptomatic mild prolapse from getting worse.

REFERENCES

1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn* 2010;29:4-20.
2. Slieker-ten Hove MC, Pool-Goudzwaard AL, Eijkemans MJ, Steegers-Theunissen RP, Burger CW, Vierhout ME. The prevalence of pelvic organ prolapse symptoms and signs and their relation with bladder and bowel disorders in a general female population. *Int Urogynecol J Pelvic Floor Dysfunct* 2009;20:1037-1045.
3. Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. *JAMA* 2008;300:1311-1316.
4. Gutman RE, Ford DE, Quiroz LH, Shippey SH, Handa VL. Is there a pelvic organ prolapse threshold that predicts pelvic floor symptoms? *Am J Obstet Gynecol* 2008;199:683.e1-7.
5. Swift S, Woodman P, O'Boyle A, et al. Pelvic Organ Support Study (POSST): the distribution, clinical definition, and epidemiologic condition of pelvic organ support defects. *Am J Obstet Gynecol* 2005;192:795-806.
6. Wu JM, Kawasaki A, Hundley AF, Dieter AA, Myers ER, Sung VW. Predicting the number of women who will undergo incontinence and prolapse surgery, 2010 to 2050. *Am J Obstet Gynecol* 2011;205:230.e1-5.
7. Hagen S, Stark D, Glazener C, Sinclair L, Ramsay I. A randomized controlled trial of pelvic floor muscle training for stages I and II pelvic organ prolapse. *Int Urogynecol J Pelvic Floor Dysfunct* 2009;20:45-51.
8. Stüpp L, Resende AP, Oliveira E, Castro RA, Girao MJ, Sartori MG. Pelvic floor muscle training for treatment of pelvic organ prolapse: an assessor-blinded randomized controlled trial. *Int Urogynecol J* 2011;22:1233-1239.
9. Bo K. Can pelvic floor muscle training prevent and treat pelvic organ prolapse? *Acta Obstet Gynecol Scand* 2006;85:263-268.
10. Ghroubi S, Kharrat O, Chaari M, Ben Ayed B, Guermazi M, Elleuch MH. Effect of conservative treatment in the management of low-degree urogenital prolapse. *Ann Readapt Med Phys* 2008;51:96-102.
11. Braekken IH, Majida M, Engh ME, Bo K. Can pelvic floor muscle training reverse pelvic organ prolapse and reduce prolapse symptoms? An assessor-blinded, randomized, controlled trial. *Am J Obstet Gynecol* 2010;203:170.e1-7.
12. Kashyap R, Jain V, Singh A. Comparative effect of 2 packages of pelvic floor muscle training on the clinical course of stage I-III pelvic organ prolapse. *Int J Gynaecol Obstet* 2013;121:69-73.
13. Piya-Anant M, Therasakvichaya S, Leelaphatanadit C, Techatrisak K. Integrated health research program for the Thai elderly: prevalence of genital prolapse and effectiveness of pelvic floor exercise to prevent worsening of genital prolapse in elderly women. *J Med Assoc Thai* 2003;86:509-515.

14. Hagen S, Stark D, Glazener C, et al. Individualised pelvic floor muscle training in women with pelvic organ prolapse (POPPY): a multicentre randomised controlled trial. *Lancet* 2014;383:796-806.
15. Wiegersma M, Panman CMCR, Kollen BJ, et al. Pelvic floor muscle training versus watchful waiting or pessary treatment for pelvic organ prolapse (POPPS): design and participant baseline characteristics of two parallel pragmatic randomized controlled trials in primary care. *Maturitas* 2014;77:168-173.
16. Messelink B, Benson T, Berghmans B, et al. Standardization of terminology of pelvic floor muscle function and dysfunction: report from the pelvic floor clinical assessment group of the International Continence Society. *Neurourol Urodyn* 2005;24:374-380.
17. Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. *Am J Obstet Gynecol* 1996;175:10-17.
18. Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). *Am J Obstet Gynecol* 2005;193:103-113.
19. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220-233.
20. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to score version 2 of the SF-12 Health Survey (with a supplement documenting version 1). QualityMetric Incorporated, 2002.
21. Rogers RG, Coates KW, Kammerer-Doak D, Khalsa S, Qualls C. A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). *Int Urogynecol J Pelvic Floor Dysfunct* 2003;14:164-168.
22. Culligan PJ, Scherer J, Dyer K, et al. A randomized clinical trial comparing pelvic floor muscle training to a Pilates exercise program for improving pelvic muscle strength. *Int Urogynecol J* 2010;21:401-408.
23. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. *BMJ* 2001;323:1123-1124.
24. Smith PP, Appell RA. Pelvic organ prolapse and the lower urinary tract: the relationship of vaginal prolapse to stress urinary incontinence. *Curr Urol Rep* 2005;6:340-347.
25. De Boer TA, Salvatore S, Cardozo L, et al. Pelvic organ prolapse and overactive bladder. *Neurourol Urodyn* 2010;29:30-39.
26. Romanzi LJ, Chaikin DC, Blaivas JG. The effect of genital prolapse on voiding. *J Urol* 1999;161:581-6.
27. Burrows LJ, Meyn LA, Walters MD, Weber AM. Pelvic symptoms in women with pelvic organ prolapse. *Obstet Gynecol* 2004;104:982-988.
28. Thakar R, Stanton S. Management of genital prolapse. *BMJ* 2002;324:1258-1262.
29. Hagen S, Glazener C, Cook J, Herbison P, Toosz-Hobson P. Further properties of the pelvic prolapse symptom score: minimally important change and test-retest reliability. *Neurourol Urodyn* 2010;29:1055-1056.
30. Gelhorn HL, Coyne KS, Sikirica V, Gauld J, Murphy M. Psychometric evaluation of health-related

- quality-of-life measures after pelvic organ prolapse surgery. *Female Pelvic Med Reconstr Surg* 2012;18:221-226.
31. Utomo E, Blok BF, Steensma AB, Korfage IJ. Validation of the Pelvic Floor Distress Inventory (PFDI-20) and Pelvic Floor Impact Questionnaire (PFIQ-7) in a Dutch population. *Int Urogynecol J* 2014;25:531-544.
 32. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. *J Clin Epidemiol* 2008;61:102-109.

APPENDIX I SCREENING QUESTIONNAIRE

Do you have a sensation of/have you ever seen a bulge in your vagina?

Do you have a sensation of pelvic heaviness or pressure?

Do you ever leak urine?

Do you have to press to the vaginal wall to start or complete voiding?

Do you have to press to the vaginal wall to start or complete defecation?

APPENDIX II PFMT LIFESTYLE AND TOILET ADVICE AND EXERCISE PROGRAM

Lifestyle advices

- Avoid heavy lifting.
- Avoid constipation: drink at least 1.5-2 liters of fluids daily and eat plenty of fiber (whole meal products, vegetables, fruit). Ask your general practitioner for a laxative if this is not sufficient.
- Use the Knack exercise before and during any increases abdominal pressure.
- If smoking: try to stop.
- If overweight: try to lose weight.

Toilet instructions

- Keep your feet flat on the floor.
- Micturition: sit up straight (concave back), relax your pelvic floor, do not strain.
- Defecation: go to the toilet if you feel the urge to defecate, sit down with a convex back, relax your pelvic floor and take your time. If necessary, strain slightly but keep breathing.

Basic exercises program

- Perform 3 series of 8-12 fast contractions of 1 second followed by 1 second of relaxation. Take 30-60 seconds of rest between series.
- Perform 3 series of 8-12 contractions of 6-10 seconds followed by 6-10 seconds of relaxation. Take 1-2 minutes of rest between series.
- Perform a (nearly) maximal contraction and hold this for 6-10 seconds, try to make 3-5 fast contractions of 1 second on top of the maximal contraction. Repeat this exercise 3 times and take 1-2 minutes of rest between exercises.*

Examples of additional exercises*

- Perform a step wise contraction: start at 30%, followed by 60%, up to 100% and also perform a stepwise relaxation: from 100% to 60% to 30% to complete relaxation. Repeat this exercise 3 times and take 1-2 minutes of rest between exercises.
- To focus on the ventral part of the pelvic floor: perform your basic exercises while sitting on a chair with a concave back and your feet positioned on the floor with your toes pointing inwards.
- To focus on the dorsal part of the pelvic floor: perform your basic exercises while sitting on a chair with a convex back and your feet positioned on the floor with your toes pointing outwards.
- Perform a contraction starting at the dorsal part of the pelvic floor, moving to the ventral part of the pelvic floor (like 'closing a zipper'). Repeat this exercise 3 times and take 1-2 minutes of rest between exercises.

*Not in participants with an overactive pelvic floor

